glp 1 ddp4 Cardiovascular effects of the DPP-4 inhibitors Dipeptidyl Peptidase (DPP)-IV Inhibitors with

GLP-1-based therapies should be used with caution in pregnancy or breastfeeding, and the risk of hypoglycaemia is increased when these agents are used alongside insulin or sulfonylureas

It could cause structural or functional neurodevelopmental abnormalities responsible for ASD and ADHD

This tissue absorbs peptides into the bloodstream rapidly, bypassing the digestive system (which would destroy oral peptides) without requiring injection

Early signs that a dose adjustment might be needed

A 2021 New England Journal of Medicine trial showed participants on semaglutide lost an average of 15.3 kg compared to 2.6 kg in the placebo group over 68 weeks